HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 34 of 34
Establishes a set of definitions, policies, and procedures to guide the involvement of individuals such as long-term collaborators, high school and college-level students, graduate students, and others who are not regular CHOP employees in the Research Institute’s programs.
Dr. Germiller is an attending surgeon and director of clinical research in the Division of Otolaryngology. His research interests include hearing loss in children, disorders of inner ear and auditory nerve development, cochlear implantation, congenital abnormalities, and genetics of hearing disorders.
Dr. Ginsburg’s research focuses on facilitating youth to develop their own solutions to social problems and to teach clinicians how to better serve them. His current focus is on translating the best of what is known from research and practice into practical approaches parents, professionals, and communities can use to build resilience.
Dr. Glatz is a pediatric interventional cardiologist conducting rigorously designed clinical research. He has formal Masters-level training in study design, epidemiology, and biostatistics. Dr. Glatz has an extensive record of research productivity, including multiple collaborative projects, focused on outcomes research in the content area of pediatric cardiology.
Dr. Glessner’s current research focuses on childhood neuropsychiatric and neurodevelopmental disorders along with the genetic architecture associated with them, including single nucleotide polymorphisms, single nucleotide variations, and copy number variations ascertained by genomic technologies.
Dr. Gmuca seeks to enhance the care of children with chronic musculoskeletal pain. Her current research addresses amplified musculoskeletal pain syndrome, which is a major public health issue because of its high prevalence, related socioeconomic burden, and associated risk of opioid exposure. Dr. Gmuca’s work aims to identify innovative strategies to improve long-term treatment outcomes for this patient population.
Dr. Goldberg's research program focuses on investigating cerebral cortical circuit function and dysfunction in neurodevelopmental disorders. Using a variety of research techniques, Dr. Goldberg has a specific research interest in the workings of neuron subtype called GABAergic inhibitory interneuron and the role of interneuron dysfunction in disease.
Dr. Goldberg's research focuses on children with single ventricle congenital heart disease. Much of his work centers on the consequences of the abnormal single ventricle physiology and the impact on other organ systems throughout the body. He is also interested in medical interventions designed to improve the efficiency of the post-Fontan circulation by lowering pulmonary vascular resistance.
Dr. Goldfarb has special interests in the treatment of children with end-stage lung disease such as cystic fibrosis, interstitial lung disease, pulmonary late effects of oncology treatments, and other pulmonary disorders.
Dr. Goldmuntz's research focuses on the genetic basis and modifiers of congenital heart disease, cardiomyopathy, and heart failure. Her goal is to identify genetic alterations conferring a risk for congenital heart disease and to correlate these findings with clinical outcomes. To this end, she is also performing clinical translational studies.
Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.
Dr. Gottardi leads the Bioengineering and Biomaterials (Bio2) lab, collaborating on clinical and research efforts to offer engineering solutions for pediatric health, primarily treatments for airway disorders. Dr. Gottardi researches mechanisms of laryngotracheal pathologies, applies tissue engineering to improve pediatric conditions, develops new devices, and formulates controlled drug delivery systems to treat and improve patients’ lives.
Dr. Graci aims to identify the mechanisms underlying injury to inform strategies and interventions to reduce injury and improve safety. She leverages her eclectic scientific background, spanning from experimental psychology to exercise science and biomechanics. Her research focuses on biomechanical risk factors for age-related falls, and injury mechanisms due to motor vehicle accidents.
Dr. Green’s long-term goal is to elucidate the sources of DNA damage in childhood leukemia in order to develop better therapies and ultimately improve outcomes. She specifically studies the intersection of immune responses to viral infection and genome instability, working closely with virologists, oncologists, and geneticists at Children’s Hospital of Philadelphia, Penn, and nationwide.
Dr. Gregory's overall career goal is to develop clinical programs to decrease rates of preterm birth. As a pediatric primary care physician-researcher, she seeks to leverage existing pediatric systems and opportunities for care to achieve this goal.
Dr. Grimberg investigates the growth hormone (GH)/insulin-like growth factor (IGF)-I axis and clinical issues related to child growth. Her recent research is focused on disparities in, and the decision-making related to, the medical management of children with short stature. She is fascinated by how differential societal pressures for tallness and the advent of an expensive therapeutic have transformed a fundamental aspect of pediatric healthcare.
Dr. Grinspan's research program focuses on oligodendrocytes, cells of the central nervous system that synthesize the myelin sheath required for transmission of nervous impulses. Her research seeks to understand the signaling pathways that regulate oligodendrocyte maturation and how they are perturbed in diseases such as multiple sclerosis, HIV, and perinatal white matter injury.
Dr.Grundmeier’s research focuses on maximizing the existing and future potential of electronic health records (EHRs) for clinical research and knowledge delivery, with an overarching goal of improving health and healthcare for children.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
Dr. Guevara is the principal investigator on research grants evaluating health inequities in early childhood development and behavioral problems. He utilizes community-based participatory clinical trials involving parent advocacy groups, community organizations, and government agencies to test the effects of psychosocial interventions designed to provide parents with resources and tools to improve the care of their children.